A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research
- Authors
- Oh, DY[Oh, Do-Youn]; Lee, KW[Lee, Keun Wook]; Lee, KH[Lee, Kyung-Hee]; Sohn, CH[Sohn, Chang-Hak]; Park, YS[Park, Young Suk]; Zang, DY[Zang, Dae Young]; Ryoo, HM[Ryoo, Hun-Mo]; Song, HS[Song, Hong-Suk]; Kim, JS[Kim, Jin-Soo]; Kang, HJ[Kang, Hye-Jin]; Kim, BS[Kim, Bong-Seog]; Bang, YJ[Bang, Yung-Jue]
- Issue Date
- Jun-2012
- Publisher
- SPRINGER
- Keywords
- Erlotinib; Gemcitabine; Capecitabine; Pancreatic c
- Citation
- INVESTIGATIONAL NEW DRUGS, v.30, no.3, pp.1164 - 1174
- Indexed
- SCIE
SCOPUS
- Journal Title
- INVESTIGATIONAL NEW DRUGS
- Volume
- 30
- Number
- 3
- Start Page
- 1164
- End Page
- 1174
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/65208
- DOI
- 10.1007/s10637-011-9651-3
- ISSN
- 0167-6997
- Abstract
- Background To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC). Methods Locally advanced PC was excluded. Erlotinib was given at a dose of 100 mg daily from D1 to D28. 1000 mg/m(2) of gemcitabine was given on D1,8,15 and 1660 mg/m(2)/day of capecitabine was given from D1 to 21, repeated every 4 weeks. Response was assessed every 8 weeks. Results A total of 47 patients were enrolled. Response rate and disease control rate was 32.6% (95% CI, 18.6-46.6%) and 83.7% (95% CI, 72.7-94.7%) respectively. The PFS was 6.5 months (95% CI, 3.4-9.7) and OS was 12.0 months (95% CI, 8.6-15.9). The Gr 3/4 toxicities were: neutropenia (6.8%), thrombocytopenia (3.2%), anemia (1.6%). nausea (1.6%), vomiting (1.6%), anorexia (5.3%), rash (2.4%). The EGFR expression was associated with shorter OS and ERCC2 expression was associated with longer PFS and OS. PFS and OS were not different according to K-RAS mutation or polymorphism of RRM1 and CDA. Conclusions Erlotinib, gemcitabine and capecitabine combination showed promising efficacy and good tolerability in metastatic PC. This efficacy was observed irrespective of K-RAS mutation, and EGFR expression was poor prognostic factor for OS.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/65208)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.